Drug intelligence / Profile preview

IDC333

Development stage: Preclinical
Lead developer: Prestige Biopharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

IDC333 is a novel monoclonal antibody currently in the lead identification stage of preclinical development by Prestige Biopharma. It is being developed for the treatment of various solid tumors. Classified by the developer as a "Novel Concept Antibody," it is part of an innovative pipeline aimed at addressing unmet needs in oncology. As of early 2024, the specific molecular target and detailed mechanism of action for IDC333 have not been publicly disclosed by the company.

Beyond the preview

Go deeper on IDC333.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IDC333.

Explore the full profile